Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
71. |
ECCT/20/04/02 | PROSYNK Study A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya. |
Principal Investigator(s) 1. Stephen Allen Site(s) in Kenya 1. Homa Bay County Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) 3. Migori County Referral Hospital (Migori county) 4. Rongo Sub-County Hospital (Migori county) 5. Rachuonyo Sub County Hospital (Homa Bay county) 6. Kendu Bay Sub-County Hospital (Homa Bay county) 7. Ahero County Hospital (Kisumu county) 8. Rabuor Sub-County Hospital (Kisumu county) 9. Akala Sub-County Hospital (Siaya county) 10. Bondo Sub-County Hospital (Siaya county) |
View |
72. |
ECCT/19/12/01 | BOHEMIA PK400 Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial. |
Principal Investigator(s) 1. Marta Ferreira Maia Site(s) in Kenya Kilifi |
View |
73. |
ECCT/19/10/02 | AMC-100 A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals with Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA) |
Principal Investigator(s) 1. NAFTALI WISINDI BUSAKHALA Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTER |
View |
74. |
ECCT/19/11/01 | A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults. Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults. |
Principal Investigator(s) 1. Melissa Kapulu Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
75. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
View |